top of page
  • Active, not recruiting

NCT05024045: Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

Updated: Feb 10

  • NCT05024045: Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers


LOXO 338

The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years.


Leukemia, Lymphocytic, Chronic, B-Cell

Lymphoma, B-cell Marginal Zone

Lymphoma, Non-Hodgkin

Multiple Myeloma

B-cell Lymphoma

Waldenstrom Macroglobulinemia

Lymphoma, Mantle-Cell


Sponsor

Eli Lilly and Company


Collaborator

Loxo Oncology, Inc


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT05024045


Official Title: A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies


First Posted : August 27, 2021


Click here for details on ClinicalTrials.gov

 

Drug: LOXO-338

Bcl-2 inhibitor LOXO-338

Drug: Pirtobrutinib

BTK inhibitor LOXO-305

 

Bcl-2 inhibitor LOXO-338

BTK inhibitor LOXO-305

 

Locations

United States, Florida

United States, Indiana

United States, Kansas

United States, Minnesota

United States, New York

United States, Washington

United States, Wisconsin

Europe

France

Poland

 

Comentarios


Los comentarios se han desactivado.
Posts Archive
bottom of page